U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06813417) titled 'CAR T Therapy with GCAR1 for Relapsed Alveolar Soft Part Sarcoma' on Jan. 28.
Brief Summary: a single patient study to answer the following question: Is GCAR1 safe and effective for re-treatment of alveolar soft part sarcoma (ASPS) with GPNMB surface expression that has relapsed and is not responding to usual treatment?
Study Start Date: Jan. 30
Study Type: INTERVENTIONAL
Condition:
Sarcoma
Intervention:
BIOLOGICAL: GCAR1
GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprise...